Response gene to complement-32 enhances metastatic phenotype by mediating transforming growth factor beta-induced epithelial-mesenchymal transition in human pancreatic cancer cell line BxPC-3

Journal of Experimental & Clinical Cancer Research

Qiu Zhao¹  De-Min Li¹  Hui-Zhen Zhao¹  Hui-Fang Pang¹  Sheng-Nan Xu¹  Pei-Yuan Li¹  Hua Qin¹  Liang Zhu² 

[1] Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China;Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China

关键词: Migration;    Epithelial-mesenchymal transition;    Transforming growth factor -β;    Pancreatic cancer;    Response gene to complement-32;   

Others  :  826685
DOI  :  10.1186/1756-9966-31-29

 received in 2011-12-14, accepted in 2012-03-29,  发布年份 2012

【 摘 要 】

Background

Response gene to complement-32 (RGC-32) is comprehensively expressed in many kinds of tissues and has been reported to be expressed abnormally in different kinds of human tumors. However, the role of RGC-32 in cancer remains controversial and no reports have described the effect of RGC-32 in pancreatic cancer. The present study investigated the expression of RGC-32 in pancreatic cancer tissues and explored the role of RGC-32 in transforming growth factor-beta (TGF-β)-induced epithelial-mesenchymal transition (EMT) in human pancreatic cancer cell line BxPC-3.

Methods

Immunohistochemical staining of RGC-32 and E-cadherin was performed on specimens from 42 patients with pancreatic cancer, 12 with chronic pancreatitis and 8 with normal pancreas. To evaluate the role of RGC-32 in TGF-β-induced EMT in pancreatic cancer cells, BxPC-3 cells were treated with TGF-β1, and RGC-32 siRNA silencing and gene overexpression were performed as well. The mRNA expression and protein expression of RGC-32 and EMT markers such E-cadherin and vimentin were determined by quantitative reverse transcription-PCR (qRT-PCR) and western blot respectively. Finally, migration ability of BxPC-3 cells treated with TGF-β and RGC-32 siRNA transfection was examined by transwell cell migration assay.

Results

We found stronger expression of RGC-32 and higher abnormal expression rate of E-cadherin in pancreatic cancer tissues than those in chronic pancreatitis tissues and normal pancreatic tissues. Immunohistochemical analysis revealed that both RGC-32 positive expression and E-cadherin abnormal expression in pancreatic cancer were correlated with lymph node metastasis and TNM staging. In addition, a significant and positive correlation was found between positive expression of RGC-32 and abnormal expression of E-cadherin. Furthermore, in vitro, we found sustained TGF-β stimuli induced EMT and up-regulated RGC-32 expression in BxPC-3 cells. By means of siRNA silencing and gene overexpression, we further demonstrated that RGC-32 mediated TGF-β-induced EMT and migration in BxPC-3 cells.

Conclusions

The results above indicated that RGC-32 might be a novel metastasis promoting gene in pancreatic cancer and it enhances metastatic phenotype by mediating TGF-β-induced EMT in human pancreatic cancer cell line BxPC-3.

【 授权许可】

   
2012 Zhu et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Stathis A, Moore MJ: Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010, 7:163-172.
• [2]Hidalgo M: Pancreatic cancer. N Engl J Med 2010, 362:1605-1617.
• [3]Polyak K, Weinberg RA: Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009, 9:265-273.
• [4]Thiery JP, Acloque H, Huang RY, Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
• [5]Truty MJ, Urrutia R: Basics of TGF-beta and pancreatic cancer. Pancreatology 2007, 7:423-435.
• [6]Ellenrieder V, Hendler SF, Boeck W, Seufferlein T, Menke A, Ruhland C, Adler G, Gress TM: Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res 2001, 61:4222-4228.
• [7]Bardeesy N, Cheng KH, Berger JH, Chu GC, Pahler J, Olson P, Hezel AF, Horner J, Lauwers GY, Hanahan D, DePinho RA: Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 2006, 20:3130-3146.
• [8]Levy L, Hill CS: Smad4 dependency defines two classes of transforming growth factor beta (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol Cell Biol 2005, 25:8108-8125.
• [9]Vogelmann R, Nguyen-Tat MD, Giehl K, Adler G, Wedlich D, Menke A: TGFbeta-induced downregulation of E-cadherin-based cell-cell adhesion depends on PI3-kinase and PTEN. J Cell Sci 2005, 118:4901-4912.
• [10]Badea TC, Niculescu FI, Soane L, Shin ML, Rus H: Molecular cloning and characterization of RGC-32, a novel gene induced by complement activation in oligodendrocytes. J Biol Chem 1998, 273:26977-26981.
• [11]Badea T, Niculescu F, Soane L, Fosbrink M, Sorana H, Rus V, Shin ML, Rus H: RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase. J Biol Chem 2002, 277:502-508.
• [12]Li F, Luo Z, Huang W, Lu Q, Wilcox CS, Jose PA, Chen S: Response gene to complement 32, a novel regulator for transforming growth factor-beta-induced smooth muscle differentiation of neural crest cells. J Biol Chem 2007, 282:10133-10137.
• [13]Fosbrink M, Cudrici C, Niculescu F, Badea TC, David S, Shamsuddin A, Shin ML, Rus H: Overexpression of RGC-32 in colon cancer and other tumors. Exp Mol Pathol 2005, 78:116-122.
• [14]Saigusa K, Imoto I, Tanikawa C, Aoyagi M, Ohno K, Nakamura Y, Inazawa J: RGC32, a novel p53-inducible gene, is located on centrosomes during mitosis and results in G2/M arrest. Oncogene 2007, 26:1110-1121.
• [15]Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise TA, Massagué J: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549.
• [16]Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W, Michalopoulos G, Becich M, Monzon FA: Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 2007, 7:64. BioMed Central Full Text
• [17]Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (Eds): AJCC cancer staging manual 7th edition. New York: Springer; 2010.
• [18]Vlaicu SI, Tegla CA, Cudrici CD, Fosbrink M, Nguyen V, Azimzadeh P, Rus V, Chen H, Mircea PA, Shamsuddin A, Rus H: Epigenetic modifications induced by RGC-32 in colon cancer. Exp Mol Pathol 2010, 88:67-76.
• [19]Jawhari A, Jordan S, Poole S, Browne P, Pignatelli M, Farthing MJ: Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: relationship with patient survival. Gastroenterology 1997, 112:46-54.
• [20]Wang Y, Zhao Q, Ma S, Yang F, Gong Y, Ke C: Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling. IUBMB Life 2007, 59:717-721.
• [21]Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2:442-454.
• [22]Cano CE, Motoo Y, Iovanna JL: Epithelial-to-mesenchymal transition in pancreatic adenocarcinoma. Scientific World Journal 2010, 10:1947-1957.
• [23]Massague J, Chen YG: Controlling TGF-beta signaling. Genes Dev 2000, 14:627-644.
• [24]Wrana JL, Attisano L: The Smad pathway. Cytokine Growth Factor Rev 2000, 11:5-13.
• [25]Wendt MK, Allington TM, Schiemann WP: Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol 2009, 5:1145-1168.
• [26]Deer EL, González-Hernández J, Coursen JD, Shea JE, Ngatia J, Scaife CL, Firpo MA, Mulvihill SJ: Phenotype and genotype of pancreatic cancer cell lines. Pancreas 2010, 39:425-435.
• [27]Wilentz RE, Iacobuzio-Donahue CA, Argani P, McCarthy DM, Parsons JL, Yeo CJ, Kern SE, Hruban RH: Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000, 60:2002-2006.
• [28]Huang WY, Li ZG, Rus H, Wang X, Jose PA, Chen SY: RGC-32 mediates transforming growth factor-beta- induced epithelial-mesenchymal transition in human renal proximal tubular cells. J Biol Chem 2009, 284:9426-9432.
• [29]Weis WI, Nelson WJ: Re-solving the cadherin- Catenin-Actin Conundrum. J Biol Chem 2006, 281:35593-35597.
• [30]von Burstin J, Eser S, Paul MC, Seidler B, Brandl M, Messer M, von Werder A, Schmidt A, Mages J, Pagel P, Schnieke A, Schmid RM, Schneider G, Saur D: E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology 2009, 137:361-371.
• [31]Pryczynicz A, Guzińska-Ustymowicz K, Kemona A, Czyzewska J: Expression of the E-cadherin-catenin complex in patients with pancreatic ductal adenocarcinoma. Folia Histochem Cytobiol 2010, 48:128-133.
• [32]Tanaka M, Kitajima Y, Edakuni G, Sato S, Miyazaki K: Abnormal expression of E-cadherin and beta-catenin may be a molecular marker of submucosal invasion and lymph node metastasis in early gastric cancer. Br J Surg 2002, 89:236-244.